Share Purchase Plan Results & Tranche 2 Placement Approved
Released
Released
Announcement PDF
ASX Announcement
27 June 2025
Share Purchase Plan Results & Tranche 2 Placement Approved
SYDNEY Australia, 27 June 2025 – Atomo Diagnostics Limited (ASX: AT1) (Atomo or the Company)
confirms that the Share Purchase Plan (“SPP”) announced to the ASX on 24 April 2025 closed 5pm
Monday, 23 June 2025. The Company received valid applications for 14,723,685 shares raising
$272,387.50 (before costs) including director participation. The Directors have accepted all valid
applications in full in accordance with the Prospectus dated 20 May 2025. The Applicants will also
receive 14,723,685 free attaching options, exercisable at $0.04 (4 cents), expiring on 27 June 2028
(“Options”).
Under the SPP, shareholders in the Company registered in Australia on the record date of 23 April 2025
(“Eligible Shareholders”) were entitled to subscribe for up to $30,000 of new fully paid ordinary shares
(“SPP Shares”) in the Company at the issue price of $0.0185 (1.85 cents) per SPP Share. The
Company reserves the right to place the SPP Shortfall which amounts to $727,612.50.
The Company also confirms that it has received shareholder approval at its EGM held on 23 June 2925
to raise $1,257,800 from the Tranche 2 Placement, announced on 24 April 2025, and will in due course
issue 67,989,186 Shares, at an issue price of $0.0185 (1.85 cents) per Share and 67,989,186 Options,
to professional, sophisticated and other exempt investors, including a Director.
The Shares will rank equally with existing shares in the Company. The Placement and SPP Shares are
to be issued today.
Managing Director & CEO & Interim Chair, John Kelly, commented:
“On behalf of the Board of Atomo Diagnostics Limited I wish to thank existing and new shareholders for
their participation in the Company’s fund-raising initiatives via the Share Purchase Plan and Placement.
With the raising complete and the Board refreshed the Company is in a strong position to move forward
with its operational activities”.
~ ENDS ~
For more information, please contact:
John Kelly
Managing Director & CEO & Interim Chair
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279
This announcement was authorised by the Board.
About Atomo
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid
diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability
across rapid point-of-care (POC) and at-home testing applications. The Company has successfully
commercialised a number of products across international markets and has supply agreements in place
for testing applications targeting infectious diseases including HIV, Active Syphilis, viral vs bacterial
differentiation, as well as the early detection of pregnancy.
See more at www.atomodiagnostics.com
Atomo Diagnostics Limited
ACN 142 925 684
Level 1, 3-5 George St Leichhardt NSW 2040
Share your feedback
Discover